The ocrelizumab phase II extension trial suggests the potential to improve the risk: Benefit balance in multiple sclerosis.
Objective Ocrelizumab inhibits relapsing multiple sclerosis when administered every six
months. Based on potential similar memory B cell depletion mechanisms with cladribine and …
months. Based on potential similar memory B cell depletion mechanisms with cladribine and …
The potential role for ocrelizumab in the treatment of multiple sclerosis: current evidence and future prospects
PS Sorensen, M Blinkenberg - Therapeutic advances in …, 2016 - journals.sagepub.com
B cells play a central role in the pathogenesis in multiple sclerosis (MS), being involved in
the activation of proinflammatory T cells, secretion of proinflammatory cytokines, and …
the activation of proinflammatory T cells, secretion of proinflammatory cytokines, and …
[HTML][HTML] Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis
Background B cells influence the pathogenesis of multiple sclerosis. Ocrelizumab is a
humanized monoclonal antibody that selectively depletes CD20+ B cells. Methods In two …
humanized monoclonal antibody that selectively depletes CD20+ B cells. Methods In two …
Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial
Background B lymphocytes are implicated in the pathogenesis of multiple sclerosis. We
aimed to assess efficacy and safety of two dose regimens of the humanised anti-CD20 …
aimed to assess efficacy and safety of two dose regimens of the humanised anti-CD20 …
Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of …
Background The safety and efficacy of ocrelizumab in primary progressive multiple sclerosis
were shown in the phase 3 ORATORIO trial. In this study, we assessed the effects of …
were shown in the phase 3 ORATORIO trial. In this study, we assessed the effects of …
Ocrelizumab versus placebo in primary progressive multiple sclerosis
Background An evolving understanding of the immunopathogenesis of multiple sclerosis
suggests that depleting B cells could be useful for treatment. We studied ocrelizumab, a …
suggests that depleting B cells could be useful for treatment. We studied ocrelizumab, a …
Ocrelizumab: a new milestone in multiple sclerosis therapy
P Mulero, L Midaglia… - Therapeutic advances in …, 2018 - journals.sagepub.com
B cells play a central role in the pathogenesis of multiple sclerosis (MS): they are involved in
the activation of pro-inflammatory T cells, secretion of pro-inflammatory cytokines and …
the activation of pro-inflammatory T cells, secretion of pro-inflammatory cytokines and …
Ocrelizumab: a review in multiple sclerosis
YY Syed - CNS drugs, 2018 - Springer
Ocrelizumab (Ocrevus®) is a humanized anti-CD20 monoclonal antibody approved for the
treatment of adults with relapsing multiple sclerosis (RMS) or primary progressive multiple …
treatment of adults with relapsing multiple sclerosis (RMS) or primary progressive multiple …
Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: results from the phase 3 randomized OPERA I, OPERA II, and …
Background Ocrelizumab is an infusible humanized monoclonal antibody that selectively
depletes CD20+ B cells. Infusion-related reactions (IRRs) were summarized from the …
depletes CD20+ B cells. Infusion-related reactions (IRRs) were summarized from the …
Ocrelizumab: a review in multiple sclerosis
YN Lamb - Drugs, 2022 - Springer
Ocrelizumab (Ocrevus®) is an intravenously administered, humanized anti-CD20
monoclonal antibody approved for the treatment of adults with relapsing forms of multiple …
monoclonal antibody approved for the treatment of adults with relapsing forms of multiple …